vilanterol and umeclidinium bromide

R03AL03

Forms & Strengths

Adult Dosing

Chronic Obstructive Pulmonary Disease (COPD): 1 inhalation (62.5 mcg/25 mcg) once daily orally at the same time of day

Pediatric Dosing

Safety and efficacy in pediatric patients (<18 years) have not been established; not indicated for use in children

Indications

Long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema
Reduction of COPD exacerbations

Mechanism of Action

Umeclidinium is a long-acting muscarinic antagonist (LAMA) that inhibits the muscarinic M3 receptor on airway smooth muscle, causing bronchodilation
Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates intracellular adenylate cyclase, increasing cyclic AMP and causing smooth muscle relaxation and bronchodilation

Contraindications

Hypersensitivity to umeclidinium, vilanterol, or any component of the formulation
Severe hypersensitivity to milk proteins (contains lactose)

Adverse Reactions

Drug Interactions

Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): May increase systemic exposure to vilanterol, increasing cardiovascular adverse effects; use with caution
Beta-blockers: May antagonize the therapeutic effects of vilanterol and produce severe bronchospasm in COPD patients; cardioselective beta-blockers should be used only if medically necessary
Other anticholinergic agents: Concomitant use may potentiate anticholinergic adverse effects such as dry mouth, constipation, and urinary retention

Curated Content: Needs Vetting Before Put to Clinical Use